Skip to content
MARKETS / BALCAO / KOAN
BALCAO · SERVICES-PREPACKAGED SOFTWARE · SMALL CAP

Resonate Blends, Inc. KOAN

13 fiscal years on record · USD · FY2024 reported · SEC filings only
$1.9M
▲ 11414.5% YoY
$-2.1M
$-1.0M
▼ 10232.4% YoY
In brief

What this company does

Our company engages in the discovery, development and marketing of products designed to better mankind. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual’s ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Research and development activities center on exploring other areas, such as Secretogues that can naturally enhance a person’s own growth hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, legally and utilizing known body mechanisms without the use of drugs.

Written from the business description in Resonate Blends, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 10 June 2025. Every sentence was checked against that document before publication.

Growth
USD 1.9M
Revenue, FY2024 · full 13-year series below
Revenue $M Net income $M
FY2024 · Revenue 1.9 · Net income -2.1
0.8M1.6M-4.0M2012201420162018202020222024
Compound annual growth
+312.4%
+12.5%
+18.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−112 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -89.5% · Net -112.5%
-10000%-20000%2012201420162018202020222024
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -1.0
-1M-2M2012201420162018202020222024

Total assetsUSD 1.9M
EquityUSD -3.2M
CashUSD 8,048.00
Current ratio0.20×

Equity funds -173% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018201720162015201420132012
Revenue $B0.00.00.00.0·0.00.00.00.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EBITDA $B·−0.0−0.0−0.0··−0.0−0.0−0.0−0.0−0.0··
Income tax $B·············
Net income $B−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·−0.0··
EPS, diluted $−0.02−0.020.01−0.19−0.08−0.31−0.08−4.26−25.18−0.04−0.010.00·
Dividend / sh $·············
Payout %·············
ROE %·············
Shares out B0.110.090.080.050.030.020.000.000.000.110.080.07·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 58 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 37 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityServices-Prepackaged Software
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image